PolyPeptide Group AG (SWX:PPGN)

Market Cap	808.29M +6.8%
Revenue (ttm)	344.49M +14.0%
Net Income	-32.42M
EPS	-0.97
Shares Out	32.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,378
Average Volume	54,088
Open	25.35
Previous Close	24.50
Day's Range	25.35 - 28.25
52-Week Range	13.22 - 32.70
Beta	1.08
RSI	58.78
Earnings Date	Mar 12, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,400
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGN

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR